started · updated
Viatris to acquire Pacira BioSciences for $1.65 billion
Viatris has entered into a definitive agreement to acquire Pacira BioSciences in an all-cash transaction valued at approximately $1.65 billion. The deal involves Viatris purchasing all outstanding shares of Pacira common stock at $36.50 per share.
The acquisition is intended to bolster Viatris’ portfolio with two established non-opioid pain therapies: Exparel, a postsurgical local analgesic, and Zilretta, an intra-articular injection for treating knee osteoarthritis pain. These products are designed to provide alternatives to traditional opioid treatments, addressing a significant medical need given the risks of dependency and side effects associated with opioids.
Viatris plans to utilize its global infrastructure and intellectual property expertise to expand the reach of these products and manage their lifecycles. The transaction has been unanimously approved by the boards of directors of both companies and is subject to customary closing conditions and regulatory approvals.
Entities
Exparel · Pacira BioSciences · Scott Smith · Viatris · Zilretta